This handout is for non-small cell lung cancer (nsclc). Your care team identified this based on: incidental or screening-detected lung nodule (nccn 2024 nsclc).
Other reasons your team may use this plan: persistent cough >3 weeks, hemoptysis, weight loss (nccn 2024 nsclc); biopsy-confirmed nsclc (nccn 2024 nsclc); age 50-80, >=20 pack-year smoking history for ldct screening (uspstf 2021).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| lobectomy | — | — | — | Anatomic resection preferred for stage I-II; mediastinal lymph node sampling required (NCCN 2024 NSCLC) |
| SBRT | — | — | — | Stereotactic body RT for medically inoperable stage I (NCCN 2024 NSCLC) |
| cisplatin | 75 mg/m2 | IV | q3w x 4 cycles | Adjuvant cisplatin-based doublet for stage II (LACE meta-analysis, Pignon JCO 2008) |
| vinorelbine | 25 mg/m2 | IV | days 1,8 q3w x 4 | Preferred cisplatin partner in adjuvant setting (LACE meta-analysis) |
| osimertinib | 80 mg | PO | once daily x 3 years | ADAURA — adjuvant osimertinib DFS benefit in EGFR-mutant resected NSCLC (Wu NEJM 2020) |
| atezolizumab | 1200 mg | IV | q3w x 16 cycles | IMpower010 — adjuvant atezolizumab after adjuvant chemo for PD-L1 >=1% (Felip Lancet 2021) |
Plan: Early-stage (I-II) — surgery +/- adjuvant
Call 911 or go to the nearest emergency room right away if you have:
Survivorship care plan, smoking cessation, palliative care integration, advance care planning, clinical trial eligibility assessment at progression (NCCN 2024 NSCLC)
Guideline: NCCN 2024 NSCLC v5 + ASCO 2023 Molecular Testing Guideline